Response to Comments: MolDX: Melanoma Risk Stratification Molecular Testing

This document is a Response to Comments for the MolDX: Melanoma Risk Stratification Molecular Testing Local Coverage Determination (L37748) and does not itself define clinical coverage criteria. It records the comment period (05/20/2021–07/03/2021), the notice period start (06/23/2022), and the LCD effective date (08/08/2022). No specific indications, limitations, documentation requirements, or frequency limits for testing are provided in this response-to-comments notice.